Quick access to up-to-date company information.
Boehringer Ingelheim initiates global Phase III study investigating nintedanib in patients with colorectal cancer
U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination
OFEV® (nintedanib) Now Available in the United States
Boehringer Ingelheim Recognized for Tenth Consecutive Year on Science Magazine’s 2014 Top Employers List
Boehringer Ingelheim and AmeriCares Partner to Expand Product Donations Program Globally
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877